The partnership will pioneer diagnostic tests for treatment response prediction and monitoring in cancer patients
HealthCare Global Enterprises (HCG) announced a research collaboration with Trucan Diagnostics, a startup specialising in advanced cancer diagnostics. The partnership aims to validate a suite of novel diagnostic tests designed to improve the detection of primary and recurrent/metastatic cancer precisely, predict therapy responses, and monitor treatment efficacy.
Under this partnership, HCG and Trucan will work together to conduct extensive validation studies on a new set of cancer diagnostic tests developed by Trucan. These tests employ advanced techniques, including next-generation sequencing and novel biomarker-driven diagnostics, to enable precise primary, recurrent/metastatic cancer detection, pre-treatment prediction of response to therapy and monitoring patients undergoing chemo or targeted therapy. The results of these studies will generate necessary data to assess and confirm the clinical utility of these tests, paving the way for their potential integration into routine clinical practice.
Dr BS Ajaikumar, Executive Chairman, Healthcare Global Enterprises, commented, “This collaboration with Trucan Diagnostics is a significant step forward in advancing India’s capabilities in precision oncology. By validating next-generation diagnostic tools developed in our Genomics laboratory at Triesta Sciences, we are not only aiming to enhance detection but also to offer highly personalised treatment planning that addresses each patient’s unique cancer profile. These innovations align with our vision to make cutting-edge, effective cancer care accessible, ultimately improving survival rates and quality of life for patients across the country.”
Dr Raman Govindarajan, Founder and CEO, Trucan Diagnostics, said, “Partnering with HCG gives us a tremendous opportunity to validate our novel diagnostic solutions in a real-world setting. We are optimistic that the outcomes of this collaboration will contribute significantly to our mission of advancing precision oncology, optimising patient care and improving overall outcomes for patients with cancer.”
